Shots:
- Genentech has reported the P-III (ALLEGORY) trial data assessing Gazyva vs PBO in ~300 adults with SLE on SoC for 52wks. followed by ~104wks. OLE period
- Trial met its 1EP, with more participants achieving ≥4-point improvement in SRI-4 at 1yr., & achieved all key 2EPs, incl. improved BICLA response & a 6-point SRI-6 improvement at 52wks., plus sustained corticosteroid control & SRI-4 from Wk. 40 to 52, & time to first flare over 52wks. per BILAG; data to be shared with the FDA & EMA
- Gazyva is being studied in membranous nephropathy & rare immune-mediated kidney diseases, with potential EC approval for lupus nephritis expected in the future
Ref: Genentech| Image: Genentech| Press Release
Related News:- Genentech Reports the US FDA’s Approval of Gazyva (Obinutuzumab) to Treat Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
